NEW HAVEN, Conn., Nov. 2, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced a poster presentation detailing the preclinical profile of ACH-3422, a uridine-analog nucleotide prodrug being advanced for the potential treatment of chronic hepatitis C viral infection (HCV). The poster is being presented at the 64 th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2013) in Washington D.C.
The poster presentation, entitled, "Preclinical Characteristics of ACH-3422: A Potent Uridine Nucleotide Prodrug for Inhibition of Hepatitis C Virus NS5B RNA Polymerase," (Poster 475; HCV Therapy: The Developmental Pipeline. Saturday, November 2, 2013: 2:00 PM – 7:30 PM ET. Poster Hall), details the potent and specific inhibition of HCV NS5B polymerase by ACH-3422, and the demonstrated low risk for mitochondrial toxicity based upon in vitro studies with human cells in static and proliferating conditions, and high efficiency in the conversion of ACH-3422 into the triphosphate within human hepatocyte cell lines. These attributes, combined with the previously reported 14-day animal toxicity study of ACH-3422, continue to support the advancement of this compound toward clinical studies for use in combination with other direct acting antiviral agents for the potential pan-genotypic treatment of chronic HCV.
"These data provide additional insight into the compelling profile of ACH-3422 as a potential NS5B nucleotide inhibitor for the broad treatment of HCV. Based upon our current development timelines, we anticipate initiating our first-in-human and proof-of-concept trials with ACH-3422 during the first half of 2014," commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. "We believe that the ability to potentially combine a potent nucleotide, such as ACH-3422, with our other proprietary assets, including our differentiated Phase 2 NS5A inhibitor, ACH-3102, and our Phase 2 protease inhibitors, including ACH-2684, provides extensive optionality for developing a simple and effective all-oral treatment regimen aimed at curing HCV across broad treatment populations."